<div id="readability-page-1"><p>In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunic, with a price target of <span id="expert-recommendation-target">$56.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Abivax SA Sponsored ADR, and Palvella Therapeutics. According to TipRanks, Slutsky has an average return of <span>43.2%</span> and a 51.21% success rate on recommended stocks. </p> <p>In a report released on May 14, Roth MKM also assigned a Buy rating to the stock with a $19.00 price target.</p></div>

IMUX

<p>LifeSci Capital's Sam Slutsky has maintained a Buy rating on Immunic (IMUX) with a price target of $56.00. Slutsky, who focuses on the Healthcare sector, has an average return of 43.2% and a 51.21% success rate on his stock recommendations. Previously, Roth MKM also assigned a Buy rating to Immunic with a price target of $19.00.</p>

Tip Ranks

Immunic

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

iShares US Pharma

VG Health

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Spyre Therapeutics

Abivax SA

Palvella Therapeutics

Immunic (IMUX) Gets a Buy from LifeSci Capital